The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Highlighting KEYTRUDA & expanding cancer pipeline
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Pharma giant targets new standards of care
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Subscribe To Our Newsletter & Stay Updated
